Growth Metrics

Soleno Therapeutics (SLNO) EBITDA Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBITDA Margin for 6 consecutive years, with 47.33% as the latest value for Q4 2025.

  • For Q4 2025, EBITDA Margin changed N/A year-over-year to 47.33%; the TTM value through Dec 2025 reached 11.08%, changed N/A, while the annual FY2025 figure was 11.0%, 7595826.0% down from the prior year.
  • EBITDA Margin hit 47.33% in Q4 2025 for Soleno Therapeutics, up from 39.82% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 3226.16% in Q1 2025 and bottomed at 14.85% in Q2 2025.